Sanofi partners with Biogen to expand accelRare rare-disease prediagnosis platform in France
PUBT · 1d ago
Share
Listen to the news
- Sanofi added Biogen to accelRare, a free rare-disease pre-diagnosis platform co-developed with 13 French rare-disease networks, Medvir.
- Biogen will promote accelRare to its healthcare network, targeting earlier suspicion of rare diseases such as Friedreich’s ataxia.
- Partnership aims to expand the platform’s algorithm, prioritizing additional high-impact rare diseases where earlier diagnosis can change care.
- accelRare, launched in 2024, targets more than 310 rare diseases, logged more than 7,000 pre-diagnoses, reported 4.54/5 physician satisfaction.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved